Earnings Call Intelligence Subscribe
Home › Call Sheets › MDT › Q2'25
Call sheet · Q2'25

Medtronic (MDT)

Q2'25 earnings call · held 2024-11-19 · compared with the Q1'25 call · management-credibility review
9/12
Disclosure score
4 medium, 2 low flags
Financial quality
Bottom line
The sleeper story is Medtronic's PFA dominance hinges on supplier relationships they don't control - their Q2 growth stall from component shortages exposes this critical dependency just as they're betting the farm on cardiac ablation. While everyone focuses on the FDA approval win for Affera, the real constraint isn't regulatory but manufacturing scale they don't own. Hypertension remains stuck in regulatory purgatory despite payment finalization, with management offering no timeline beyond continued 'engagement' with CMS. The Abbott diabetes partnership sounds strategic but could signal they're losing the CGM war to DexCom and need Abbott's installed base to stay competitive. As Geoff said, 'We are at the front end of some exciting new product cycles,' but these cycles are constrained by suppliers, regulators, and competitors in ways that could derail their FY26 acceleration thesis. My view changes if they announce a second PulseSelect supplier or provide specific CMS coverage timeline by Q3.

The 30-second version

  • Affera just got FDA approved but their real PFA story is supplier dependency they're hiding
  • Diabetes partnership with Abbott sounds strategic but could be desperation masked as choice
  • Hypertension reimbursement still stuck in 'engagement' phase after all this hype

What changed this quarter

MetricQ1'25Q2'25Change
Organic Revenue Growth5.3% (Q1)5.0% (Q2)30 bps deceleration
Adjusted EPS$1.23 (Q1)$1.26 (Q2)8% constant currency growth vs 3% reported
CAS Growth RateOver 6% (Q1)Didn't accelerate as expected due to supplier issueGrowth stalled on supply constraints
Diabetes Growth13% (Q1)11% (Q2)200 bps deceleration
Neuromodulation Growth10% (Q1)12% (Q2)200 bps acceleration
TAVR/Structural HeartHigh single digits excluding Harmony (Q1)High single digits (Q2)Consistent performance
Surgical GrowthLow single digits (Q1)Flat results (Q2)Further deceleration
Spine GrowthMid-single digits (Q1)6% worldwide, 7% US Core SpineSlight acceleration
Gross Margin65.9% (Q1)65.2% (Q2)70 bps decline but 40 bps up constant currency
Operating Margin24.4% (Q1)24.3% (Q2)100 bps up constant currency

Accountability tracked

8 new promises made4 narrative shifts flagged7 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MDT Q2'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.